Neuroendocrine tumours (NETs) are rare tumours that arise from neuroendocrine cells, the specialised cells that produce and release hormones. They are usually slow-growing, which is part of what makes them hard to manage: changes can be gradual, so clinicians need reliable ways to tell whether the disease is stable, progressing or responding to treatment [1]. Blood biomarkers can help, and chromogranin A (CgA) has long been the most widely used [2].

 

 

Where chromogranin A falls short

 

CgA is useful, but it is not always specific to the tumour. Its levels can be falsely raised by other conditions and by medications, and assays are not well standardised [2]. Proton pump inhibitors, which are commonly used to reduce stomach acid, are a good example: even a short course can raise CgA around 2.5-fold [3].  This can make results harder to interpret.

 

 

What pancreastatin offers

 

Pancreastatin is a peptide derived from CgA. It has been proposed as an alternative marker because its levels are less affected by these non-specific factors, its assay is more standardised, and its levels have been shown to correlate with tumour burden, meaning the amount of disease present [2]. In practice, this means a result may reflect what the tumour is doing more closely.

 

 

Linking levels to tumour burden and outcomes

 

In a study of 176 patients with small bowel and pancreatic NETs, those with raised pancreastatin before surgery had a median progression-free survival (the time before the disease progressed) of 1.7 years, compared with 6.5 years for those with normal levels. This held after accounting for age, tumour site and whether the disease had spread [2].

 

 

Monitoring progression and response to treatment

 

Pancreastatin may also be useful during follow-up. In 218 patients after surgery for small bowel NETs, it identified imaging-confirmed progression with 78.9% accuracy, compared with 63.3% for CgA, and the authors suggested it could replace CgA for surveillance in this setting [3].

Early evidence also points to a role in treatment monitoring. In a retrospective study of patients starting somatostatin analogue therapy, around one in three showed a rapid rise in pancreastatin, which was associated with poorer survival and could prompt consideration of alternative treatment options [4]. Larger prospective studies are needed to confirm these findings.

 

 

Pancreastatin at Randox

 

Pancreastatin is available through Randox Biochip Array Technology, a multiplex platform that measures multiple biomarkers from a single patient sample, and on the Evidence RABTA, a fully automated, random access analyser.

 

 

Reference list

 

  1. Vinik, A.I. et al. (2009) ‘Biochemical testing for neuroendocrine tumors’, Pancreas, 38, pp. 876-889.
  2. Sherman, S.K. et al. (2014) ‘Pancreastatin predicts survival in neuroendocrine tumors’, Annals of Surgical Oncology, 21(9), pp. 2971-2980. doi: 10.1245/s10434-014-3728-0.
  3. Tran, C.G. et al. (2021) ‘It is time to rethink biomarkers for surveillance of small bowel neuroendocrine tumors’, Annals of Surgical Oncology, 28(2), pp. 732-741. doi: 10.1245/s10434-020-08784-0.
  4. Stronge, R.L. et al. (2008) ‘A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours’, Annals of Clinical Biochemistry, 45, pp. 560-566. doi: 10.1258/acb.2008.008033.